1. FDA. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigation New Drug Applications (INDs), Rockville. http://www.fda.gov. Cited June10, 2016.
2. FDA. Draft Guidance for Industry: Somatic Cell Therapy for Cardiac Disease, Rockville. http://www.fda.gov. Cited June 10, 2016.
3. Sohn, H.S., Heo, J.S., Kim, H.S., Choi, Y., and Kim, H.O., Duration of in vitro storage affects the key stem cell features of human bone marrow-derived mesenchymal stromal cells for clinical transplantation, Cytotherapy, 2013, vol. 15, no. 4, pp. 460–466.
4. Chen, Y., Yu, B., Xue, G., Zhao, J., Li, R.K., Liu, Z., and Niu, B., Effects of storage solutions on the viability of human umbilical cord mesenchymal stem cells for transplantation, Cell Transplant., 2013, vol. 22, no. 6, pp. 1075–1086.
5. Lee, E.J., Lee, S.A., and Kim, J., The effect of human serum albumin on the extended storage of human oral keratinocyte viability under mild hypothermia, Cryobiology, 2005, vol. 50, no. 1, pp. 103–111.